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CASE REPORT
Recurrent Dermatofibrosarcoma Protuberans of the Parotid: A case report and
review of literature
Shayan Khalid Ghaloo, Rahim Dhanani, Hamdan Ahmed Pasha, Mohammad Sohail Awan, Aisha Memon

Abstract

Case Report

In
1924,
Darier
and
Ferrand
described
Dermatofibrosarcoma Protuberans as a progressive and
recurring dermatofibroma. It is a locally aggressive
sarcoma originating from dermal and subdermal tissue of
the skin. It usually begins as a small plaque that grows
over a period and later manifests as multiple small
subcutaneous nodules. It is more commonly found in
females as compared to males and typically occurs in
between 2nd and 5th decades of life. Most frequently
involved regions of the body are torso and proximal ends
of extremities and very rarely head and neck region is the
site of involvement. The mainstay of treatment of this
entity is surgery. The rate of recurrence of this disease is
very high in about 50% of the cases and it may also
express rare distant metastasis. It is a radiosensitive
tumour and radiation may play a role in reducing risk of
recurrence. We present a case of a 35 years old male with
recurrent Dermatofibrosarcoma Protuberans of right
parotid gland.

A 35-year-old man came to the Otolaryngology
outpatient clinic at Aga Khan University Hospital, Karachi
in November 2016 with history of a slowly enlarging mass
in the right pre-auricular region for one and half year. On
physical examination, the mass was around 4 x 5 cm in
size, located in the right parotid region and it was firm,
mobile and non-tender. There was no associated pain,
discharge, fever, or trismus and no remarkable findings on
oral examination. Facial nerve was also intact. The rest of
the head and neck examination was normal. The chest Xray and laboratory examination were unremarkable with
no evidence of metastatic disease. Initially an ultrasound
was done that revealed irregular, heterogeneous mass of
5 x 4.2 cm lying superficial to the parotid gland. The fine
needle aspiration biopsy of the mass showed spindle cell
lesion.

Keywords: Parotid gland, Dermatofibrosarcoma, Spindle
cell lesion, Recurrence, Salivary gland.

Introduction

The past history of the patient is significant in a view that
five years back he was operated for a mass in right parotid
gland. The final histopathology showed solid and smooth
cut surface of gray-white color, measuring 3 x 2 x 1 cm.
Final histopathology reported it to be spindle/fusiform
cell sarcoma, consistent with low grade fibrosarcoma.

The history of dermatofibrosarcomaprotuberans (DFSP)
dates back to 1924 when Darier and Ferrand, in 1924,
initially defined it as "progressive and recurring
dermatofibroma".1 It originates from dermal and
subdermal tissue of the skin and is locally aggressive soft
tissue sarcoma.2 The annual incidence rate of DFSP is 4.1
persons per million person-years. Incidence among
women is 1.14 times higher than in men,3 and it typically
occurs in early mid adult life i.e.; 2nd to 5th decade. It can
involve any part of the body but the torso and proximal
end of extremities are the most frequent sites of its
incidence.4 Head and neck region is a quite rare region for
this tumour to occur.5,6 Recurrence rate of DFSP is about
50% and it also expresses rare distant metastasis.7 The
gold standard treatment for this locally aggressive
tumour is surgery.8

Keeping all the parameters in view, the patient was treated
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Figure-1: Photomicrograph showing a cellular lesion closing abutting the salivary
gland parenchyma. (H&E staining, X40).
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manner.11 These irregular, tentacle-like extensions of
DFSP are supposed to be responsible for the local
recurrence following inadequate resection.12
Histopathologically, DFSP is poorly circumscribed with
tumour cells infiltrating diffusely into dermis and
subcutis. The tumour cells are composed of uniform
population of monomorphic spindle cells arranged in
storiform pattern with mitotic figures not exceeding 5 per
10 HPF.13
The American Joint Committee on Cancer has not
established a staging system for Dermatofibrosarcoma
Protuberans (DFSP). The following staging system
published
in
"Short
German
guidelines:
dermatofibrosarcomaprotuberans" is helpful clinically,14
Figure-2: Photomicrograph showing cellular spindle cell lesion with storiform pattern.
(H&E staining, X200).

with right superficial parotidectomy. Post-operative
period was uneventful and facial nerve of the patient was
saved. Gross examination revealed a tan white firm lesion
measuring 5X4.5X3.5cm. The tumour was 0.1 cm away
from inked excision margin. Light microscopic
examination revealed a highly cellular tumour closely
abutting the salivary gland tissue (Figure-1). The tumour
showed plump monomorphic spindle cells with vesicular
nuclei, inconspicuous nucleoli arranged in a
storiformpattern (Figure-2). Mitotic count of 5-6/10HPF
was noted in cellular areas. There was lesional entrapment
of adipose tissue. The immunohistochemical finding of
diffuse positivity of tumour cells with CD34+ helped in
arriving at the final conclusive diagnosis of
Dermatofibrosarcomaprotuberans (DFSP). The patient was
followed in the clinic after one year and has had no
recurrence till date along with intact facial nerve.

Discussion
Firstly defined to be "progressive and recurring
dermatofibroma" by Darier and Ferrand in 1924, DFSP
begins usually as a plaque that slowly grows over several
years. It later manifests as multiple small subcutaneous
nodules. Therefore, the "protuberant" appearance of
DFSP can only be witnessed in the fully developed
lesions.9 Usually males between 20 and 50 years get
affected by DFSP. The most common location of its
occurrence is trunk (47%), followed by lower extremity
(20%), upper extremity (18%), and then head and neck
(14%).10
DFSP is a locally aggressive tumour; it tends to grow in a
more infiltrative manner. The tumour can assume
irregular shapes and extend in a villous or finger-like
J Pak Med Assoc

u

Stage I - Primary tumour, localized disease

u

Stage II - Lymph node metastasis

u

Stage III - Distal metastasis14

The mainstay of treatment for DFSP remains to be surgery
with wide local excision with gross margins of 2
centimeters. But this may not be followed in the cases
where it involves the head and neck region, where
excision tends to have smaller margins and therefore
likelihood of positive margins is greater.15 DFSP is rarely
seen to be metastasized, but the chances of metastasis
increase with the increase in diameter. Tumours with size
10cm or above have greater chances to metastasize.16
Conventional chemotherapy appears to offer little utility,
however, treatment with the molecular targeted therapy
Imatinib, has yielded some limited but encouraging results
to date.12 DFSP is known to be a radio-sensitive tumour
and several studies have inspected the use of radiotherapy
in the treatment of DFSP. Haas et al. studied 21 patients
that were treated only with surgery had a local control of
67% while 17 patients who were treated with combined
therapy (surgery and radiation therapy) had local control
of 82%.17 Radiation therapy may be recommended for
patients if the margins of resection are positive or for
situations in which adequate wide excision alone may end
up in major cosmetic or functional deficits. Williams et al.
reported outcomes of 14 patients with DFSP who were
treated with radiation therapy with curative intent, 12
patients remained disease free from 1.0 to 23.5 years after
treatment (11 received postoperative radiation therapy
and 1 received radiation therapy alone). No severe
complications occurred after radiation.18 Postoperative
adjuvant radiation therapy may reduce the risk of
recurrence when clear surgical margins are not obtained.19
In 2015, De liz et al reported a case of 37 years old female
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who underwent surgery followed by radiation therapy and
remained free of disease after 5 years of follow up.20
Hedge et al reported a case of 42 years old lady with DFSP
of parotid region who developed recurrence after 9
months of surgical excision. Re-excision of the tumour was
performed and patient was referred for radiation
therapy.21

6.

Conclusion

9.

Dermatofibrosarcoma Protuberance is a locally
aggressive soft tissue sarcoma originating from dermal
and subdermal tissue of the skin. It rarely occurs in the
head and neck region. We report here on a case of DFSP
of parotid gland in a 35 year old gentleman who
underwent surgery and remained recurrence free till date.
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